Avelumab plus axitinib in unresectable or metastatic type B3 thymomas and thymic carcinomas (CAVEATT): a single-arm, multicentre, phase 2 trial

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 29.5K citations

Medicine, Oncology, Treatment Planning +14

Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Robert J. Motzer, Konstantin Penkov, John B.A.G. Haanen et al. · New England Journal of Medicine · 2019 · 2.5K citations · Full text

Medicine, Oncology, Pharmacotherapy +6

Follow-up study of thymomas with special reference to their clinical stages

Akira Masaoka, Yasumasa Monden, Kazuya Nakahara et al. · Cancer · 1981 · 1.7K citations

Medicine, Oncology, Surgery +17

T-cell invigoration to tumour burden ratio associated with anti-PD-1 response

Alexander C. Huang, Michael A. Postow, Robert J. Orlowski et al. · Nature · 2017 · 1.7K citations · Full text

Life Sciences, Immunology, Oncology +16

Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma

Diana Miao, Claire A. Margolis, Wenhua Gao et al. · Science · 2018 · 1.3K citations · Full text

Medicine, Molecular Genetics, Oncology +17